clinical trial · NCT07802821
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.·phase3·recruiting·n = 556
Extensive-stage Small Cell Lung CancerQLC5508QL2107TislelizumabCarboplatinCisplatinEtoposide
brief summary
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 in combination with QL2107 versus Tislelizumab plus platinum and etoposide as first-line treatment in participants with extensive-stage small cell lung cancer.
started
Oct 27, 2026
primary completion
Mar 15, 2029
completion
Jun 15, 2030
last updated
Oct 30, 2026
official title
A Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol